JP2025067909A5 - - Google Patents
Info
- Publication number
- JP2025067909A5 JP2025067909A5 JP2025004577A JP2025004577A JP2025067909A5 JP 2025067909 A5 JP2025067909 A5 JP 2025067909A5 JP 2025004577 A JP2025004577 A JP 2025004577A JP 2025004577 A JP2025004577 A JP 2025004577A JP 2025067909 A5 JP2025067909 A5 JP 2025067909A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- conjugate
- seq
- nucleotides
- transferrin receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713914P | 2018-08-02 | 2018-08-02 | |
| US62/713,914 | 2018-08-02 | ||
| US201862779161P | 2018-12-13 | 2018-12-13 | |
| US62/779,161 | 2018-12-13 | ||
| US201962855761P | 2019-05-31 | 2019-05-31 | |
| US62/855,761 | 2019-05-31 | ||
| US201962858888P | 2019-06-07 | 2019-06-07 | |
| US62/858,888 | 2019-06-07 | ||
| US201962859672P | 2019-06-10 | 2019-06-10 | |
| US62/859,672 | 2019-06-10 | ||
| PCT/US2019/044987 WO2020028861A1 (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2021529260A JP7705793B2 (ja) | 2018-08-02 | 2019-08-02 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529260A Division JP7705793B2 (ja) | 2018-08-02 | 2019-08-02 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025067909A JP2025067909A (ja) | 2025-04-24 |
| JP2025067909A5 true JP2025067909A5 (enExample) | 2025-10-17 |
Family
ID=69230803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529260A Active JP7705793B2 (ja) | 2018-08-02 | 2019-08-02 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| JP2025004577A Pending JP2025067909A (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529260A Active JP7705793B2 (ja) | 2018-08-02 | 2019-08-02 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210308272A1 (enExample) |
| EP (1) | EP3829596A4 (enExample) |
| JP (2) | JP7705793B2 (enExample) |
| KR (1) | KR20210081323A (enExample) |
| CN (1) | CN112955154A (enExample) |
| AU (2) | AU2019314538B2 (enExample) |
| CA (1) | CA3108287A1 (enExample) |
| IL (2) | IL321905A (enExample) |
| MX (1) | MX2021001283A (enExample) |
| SG (1) | SG11202100925VA (enExample) |
| WO (1) | WO2020028861A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019113393A1 (en) | 2017-12-06 | 2019-06-13 | Avidity Biosciences Llc | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| SG11202100934PA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| WO2021142217A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Thereapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of milck1 |
| WO2021195469A1 (en) * | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
| IL299666A (en) * | 2020-07-23 | 2023-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy |
| KR20230042713A (ko) * | 2020-07-23 | 2023-03-29 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 근긴장성 이영양증을 치료하기 위한 그의 용도 |
| UY39417A (es) * | 2020-09-11 | 2022-03-31 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresión de dux4, composiciones de dichos agentes, y métodos de uso |
| KR20230117182A (ko) * | 2020-12-04 | 2023-08-07 | 다인 세라퓨틱스, 인크. | 항체-올리고뉴클레오티드 복합체 및 그의 용도 |
| CA3202832A1 (en) * | 2020-12-31 | 2022-07-07 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2022309028A1 (en) | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| EP4124345A1 (en) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticles for muscle delivery |
| WO2023006985A1 (en) * | 2021-07-30 | 2023-02-02 | 4Basebio Uk Ltd | Nanoparticles and peptides for the delivery of cargos to muscle cells |
| CR20240139A (es) | 2021-09-01 | 2024-06-14 | Biogen Ma Inc | Anticuerpos del receptor antitransferrina y usos de los mismos |
| US11833221B2 (en) | 2021-09-01 | 2023-12-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds for reducing DMPK expression |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009005793A2 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| CN103167883B (zh) | 2010-07-19 | 2016-08-03 | F·C·贝内特 | 肌强直性营养障碍蛋白激酶(dmpk)表达的调节 |
| WO2013138662A1 (en) * | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
| US10111962B2 (en) | 2012-09-25 | 2018-10-30 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| SMT202300208T1 (it) * | 2012-10-23 | 2023-09-06 | Synaffix Bv | Anticorpo modificato, coniugato di anticorpo e processo per la preparazione degli stessi |
| TW201536329A (zh) * | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| US20190240346A1 (en) | 2016-06-20 | 2019-08-08 | Genahead Bio, Inc. | Antibody-drug conjugate |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
-
2019
- 2019-08-02 JP JP2021529260A patent/JP7705793B2/ja active Active
- 2019-08-02 SG SG11202100925VA patent/SG11202100925VA/en unknown
- 2019-08-02 IL IL321905A patent/IL321905A/en unknown
- 2019-08-02 MX MX2021001283A patent/MX2021001283A/es unknown
- 2019-08-02 EP EP19843799.8A patent/EP3829596A4/en active Pending
- 2019-08-02 CN CN201980062906.7A patent/CN112955154A/zh active Pending
- 2019-08-02 KR KR1020217005992A patent/KR20210081323A/ko active Pending
- 2019-08-02 US US17/264,905 patent/US20210308272A1/en not_active Abandoned
- 2019-08-02 CA CA3108287A patent/CA3108287A1/en active Pending
- 2019-08-02 WO PCT/US2019/044987 patent/WO2020028861A1/en not_active Ceased
- 2019-08-02 AU AU2019314538A patent/AU2019314538B2/en active Active
-
2021
- 2021-01-26 IL IL280425A patent/IL280425B2/en unknown
-
2025
- 2025-01-14 JP JP2025004577A patent/JP2025067909A/ja active Pending
- 2025-05-30 AU AU2025204039A patent/AU2025204039A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025067909A5 (enExample) | ||
| JPWO2020028864A5 (enExample) | ||
| JPWO2020028861A5 (enExample) | ||
| JPWO2020028857A5 (enExample) | ||
| JPWO2022026152A5 (enExample) | ||
| JPWO2020028841A5 (enExample) | ||
| JPWO2020028832A5 (enExample) | ||
| US20250249116A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| JPWO2018129384A5 (enExample) | ||
| JP2021507686A5 (enExample) | ||
| JPWO2020028840A5 (enExample) | ||
| KR20250004771A (ko) | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체의 투여 | |
| CN120282986A (zh) | 肌肉靶向复合物及其用于跳读dmd基因的外显子45的用途 | |
| EA035756B1 (ru) | Композиции и способы ингибирования экспрессии генов вируса гепатита в | |
| JPWO2021142313A5 (enExample) | ||
| JPWO2022020107A5 (enExample) | ||
| JPWO2022020106A5 (enExample) | ||
| JPWO2021142275A5 (enExample) | ||
| JPWO2021142227A5 (enExample) | ||
| JPWO2021142234A5 (enExample) | ||
| JPWO2022020108A5 (enExample) | ||
| JPWO2023283531A5 (enExample) | ||
| US12247047B2 (en) | Arnatar compounds and methods for enhanced cellular uptake | |
| JPWO2022147209A5 (enExample) | ||
| JPWO2022147207A5 (enExample) |